Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361679 | 0.90 | KCNH2 (0.44) | KCNH2CACNA1INAMPTDRD2DRD3 | |
| SCHEMBL18838355 | 0.90 | KCNH2 (0.44) | KCNH2CACNA1INAMPTDRD2DRD3 | |
| SCHEMBL18838491 | 0.86 | MAPT (0.46) | KCNH2CACNA1IPOLB | |
| SCHEMBL18838485 | 0.85 | KCNH2 (0.47) | KCNH2CACNA1ICACNA1HPOLBNAMPT | |
| SCHEMBL18838415 | 0.84 | CACNA1I (0.46) | KCNH2CACNA1ICACNA1HNAMPTHRH1 | |
| SCHEMBL18838325 | 0.84 | KCNH2 (0.62) | KCNH2CACNA1ICACNA1HHRH1CACNA1G | |
| SCHEMBL18838444 | 0.82 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HNAMPTHRH1 | |
| SCHEMBL18838424 | 0.82 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HNAMPTHRH1 | |
| SCHEMBL29364774 | 0.82 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HNAMPTHRH1 | |
| SCHEMBL18838423 | 0.82 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HNAMPTHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KCNH2 55/4885CACNA1I 1/4885CACNA1H 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.